Lena Friberg
Professor at Department of Pharmacy; Pharmacokinetics and Pharmacodynamics
- Mobile phone:
- +46 70 425 02 03
- E-mail:
- lena.friberg@uu.se
- Visiting address:
- Biomedicinskt Centrum BMC, Husargatan 3
- Postal address:
- Box 580
751 23 UPPSALA
Short presentation
Lena Friberg was promoted to Professor of Pharmacometrics in 2014 and is since 2021 employed as Professor of Pharmacokinetics and Pharmacodynamics. Her research focuses on translation and dose optimization within oncology and infectious diseases, by advancing concepts for interpretation and integration of in vitro, in vivo and clinical data through PKPD-modelling. Developed methodology facilitates transition between drug development stages while considering both desired and adverse effects.
Keywords
- immune system
- cancer
- antibiotics
- antibiotic resistance
- preclinical
- translational research
- non-linear mixed effects modelling
- pharmacokinetics
- pharmacometrics
- pharmacodynamics
- translational medicine
- modeling and simulation
- anticancer therapy
- bacterial infections
- drug development
- drug usage
- vaccines
Biography
Lena is since 2021 employed as Professor of Pharmacokinetics and Pharmacodynamics (Professor of Pharmacometrics 2014-2021). She obtained her PhD in 2003 and in 2007 she became Docent (Associate professor). During 2003-2008 she was supported by a personal grant from Knut & Alice Wallenberg foundation for a postdoc at the University of Queensland, Australia, and as a researcher at Uppsala University.
The research focuses on developing approaches for predictive translation of effects from preclinical data to patients, both for desired outcomes and adverse events. Important achievements include frameworks to be applied for optimized dosing strategies of new and available drugs in the areas of oncology and infection.
Lena has published >190 peer-reviewed research articles and has an h-index of 56. She has been main (co) supervisor of 12 (10) students to PhD degree and is currently supervising 9 (4) PhD students, in addition to mentoring Postdocs and early researchers. She holds competitive grants from Swedish Research Council, Swedish Cancer Society, Swedish Childhood Cancer Fund, Innovative Medicines Initiative (EU-IMI2) and Marie Skłodowska-Curie Innovative Training Networks (ITN). Lena has received the Giorgio Segré Prize from EUFEPS for “distinct research in the Pharmacokinetic-Pharmacodynamic area”, the Innovation award from ISoP and been appointed ISoP fellow and Key Scientist" by Vinnova/BioSweden. She is since 2023 the Head of Department of Pharmacy.

Publications
Selection of publications
Part of Journal of Antimicrobial Chemotherapy, p. 2984-2993, 2019
- DOI for Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen
- Download full text (pdf) of Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen
Part of Clinical Pharmacology and Therapeutics, p. 486-495, 2019
Part of Journal of Pharmaceutical Sciences, p. 630-640, 2019
- DOI for Model-Based Drug Development in Pulmonary Delivery: Pharmacokinetic Analysis of Novel Drug Candidates for Treatment of Pseudomonas aeruginosa Lung Infection
- Download full text (pdf) of Model-Based Drug Development in Pulmonary Delivery: Pharmacokinetic Analysis of Novel Drug Candidates for Treatment of Pseudomonas aeruginosa Lung Infection
Part of British Journal of Clinical Pharmacology, p. 490-500, 2018
Part of Basic & Clinical Pharmacology & Toxicology, p. 407-422, 2018
Semi-mechanistic pharmacokinetic-pharmacodynamic modelling of antibiotic drug combinations
Part of Clinical Microbiology and Infection, p. 697-706, 2018
Predicting mutant selection in competition experiments with ciprofloxacin-exposed Escherichia coli
Part of International Journal of Antimicrobial Agents, p. 399-406, 2018
Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 69-79, 2017
- DOI for A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection.
- Download full text (pdf) of A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection.
Part of CPT, p. 173-181, 2016
- DOI for PK-PD Modeling of Individual Lesion FDG-PET Response to Predict Overall Survival in Patients With Sunitinib-treated Gastrointestinal Stromal Tumor
- Download full text (pdf) of PK-PD Modeling of Individual Lesion FDG-PET Response to Predict Overall Survival in Patients With Sunitinib-treated Gastrointestinal Stromal Tumor
Part of British Journal of Clinical Pharmacology, p. 717-727, 2016
Part of British Journal of Clinical Pharmacology, p. 56-71, 2015
- DOI for Population pharmacokinetic pharmacodynamic modelling in oncology: a tool for predicting clinical response
- Download full text (pdf) of Population pharmacokinetic pharmacodynamic modelling in oncology: a tool for predicting clinical response
Recent publications
Part of JAC - Antimicrobial Resistance, 2025
- DOI for A model-based evaluation of the pharmacokinetics-pharmacodynamics (PKPD) of avibactam in combination with ceftazidime
- Download full text (pdf) of A model-based evaluation of the pharmacokinetics-pharmacodynamics (PKPD) of avibactam in combination with ceftazidime
Part of International Journal of Antimicrobial Agents, 2025
- DOI for An integrative and translational PKPD modelling approach to explore the combined effect of polymyxin B and minocycline against Klebsiella pneumoniae
- Download full text (pdf) of An integrative and translational PKPD modelling approach to explore the combined effect of polymyxin B and minocycline against Klebsiella pneumoniae
Plasma effects on bacterial time-kill dynamics: Insights from a PK/PD modelling analysis
Part of International Journal of Antimicrobial Agents, 2025
- DOI for Plasma effects on bacterial time-kill dynamics: Insights from a PK/PD modelling analysis
- Download full text (pdf) of Plasma effects on bacterial time-kill dynamics: Insights from a PK/PD modelling analysis
Part of International Journal of Antimicrobial Agents, 2025
- DOI for Ceftazidime-avibactam (CAZ-AVI) pharmacokinetics in critically ill patients undergoing continuous venovenous hemodiafiltration (CVVHDF)
- Download full text (pdf) of Ceftazidime-avibactam (CAZ-AVI) pharmacokinetics in critically ill patients undergoing continuous venovenous hemodiafiltration (CVVHDF)
Integrated modeling of biomarkers, survival and safety in clinical oncology drug development
Part of Advanced Drug Delivery Reviews, 2025
- DOI for Integrated modeling of biomarkers, survival and safety in clinical oncology drug development
- Download full text (pdf) of Integrated modeling of biomarkers, survival and safety in clinical oncology drug development
All publications
Articles in journal
Part of JAC - Antimicrobial Resistance, 2025
- DOI for A model-based evaluation of the pharmacokinetics-pharmacodynamics (PKPD) of avibactam in combination with ceftazidime
- Download full text (pdf) of A model-based evaluation of the pharmacokinetics-pharmacodynamics (PKPD) of avibactam in combination with ceftazidime
Part of International Journal of Antimicrobial Agents, 2025
- DOI for An integrative and translational PKPD modelling approach to explore the combined effect of polymyxin B and minocycline against Klebsiella pneumoniae
- Download full text (pdf) of An integrative and translational PKPD modelling approach to explore the combined effect of polymyxin B and minocycline against Klebsiella pneumoniae
Plasma effects on bacterial time-kill dynamics: Insights from a PK/PD modelling analysis
Part of International Journal of Antimicrobial Agents, 2025
- DOI for Plasma effects on bacterial time-kill dynamics: Insights from a PK/PD modelling analysis
- Download full text (pdf) of Plasma effects on bacterial time-kill dynamics: Insights from a PK/PD modelling analysis
Part of International Journal of Antimicrobial Agents, 2025
- DOI for Ceftazidime-avibactam (CAZ-AVI) pharmacokinetics in critically ill patients undergoing continuous venovenous hemodiafiltration (CVVHDF)
- Download full text (pdf) of Ceftazidime-avibactam (CAZ-AVI) pharmacokinetics in critically ill patients undergoing continuous venovenous hemodiafiltration (CVVHDF)
Integrated modeling of biomarkers, survival and safety in clinical oncology drug development
Part of Advanced Drug Delivery Reviews, 2025
- DOI for Integrated modeling of biomarkers, survival and safety in clinical oncology drug development
- Download full text (pdf) of Integrated modeling of biomarkers, survival and safety in clinical oncology drug development
Part of Journal of Antimicrobial Chemotherapy, p. 3150-3159, 2024
- DOI for Model-based translation of results from in vitro to in vivo experiments for afabicin activity against Staphylococcus aureus
- Download full text (pdf) of Model-based translation of results from in vitro to in vivo experiments for afabicin activity against Staphylococcus aureus
Part of International Journal of Antimicrobial Agents, 2024
- DOI for Physiologically-based pharmacokinetic modelling in sepsis: A tool to elucidate how pathophysiology affects meropenem pharmacokinetics
- Download full text (pdf) of Physiologically-based pharmacokinetic modelling in sepsis: A tool to elucidate how pathophysiology affects meropenem pharmacokinetics
Part of Journal of Antimicrobial Chemotherapy, 2024
- DOI for Therapeutic drug monitoring (TDM) of β-lactam/β-lactamase inhibitor (BL/BLI) drug combinations: insights from a pharmacometric simulation study
- Download full text (pdf) of Therapeutic drug monitoring (TDM) of β-lactam/β-lactamase inhibitor (BL/BLI) drug combinations: insights from a pharmacometric simulation study
Part of Leukemia, p. 712-719, 2024
- DOI for Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia
- Download full text (pdf) of Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia
Part of International Journal of Antimicrobial Agents, 2024
- DOI for PK/PD modelling and simulation of longitudinal meropenem in vivo effects against Escherichia coli and Klebsiella pneumoniae strains with high MICs
- Download full text (pdf) of PK/PD modelling and simulation of longitudinal meropenem in vivo effects against Escherichia coli and Klebsiella pneumoniae strains with high MICs
Part of PharmacoEconomics (Auckland), 2024
- DOI for Comparative Analysis of Traditional and Pharmacometric-Based Pharmacoeconomic Modeling in the Cost-Utility Evaluation of Sunitinib Therapy
- Download full text (pdf) of Comparative Analysis of Traditional and Pharmacometric-Based Pharmacoeconomic Modeling in the Cost-Utility Evaluation of Sunitinib Therapy
Part of Journal of Antimicrobial Chemotherapy, 2024
- DOI for Model-informed drug development for antimicrobials: translational pharmacokinetic-pharmacodynamic modelling of apramycin to facilitate prediction of efficacious dose in complicated urinary tract infections
- Download full text (pdf) of Model-informed drug development for antimicrobials: translational pharmacokinetic-pharmacodynamic modelling of apramycin to facilitate prediction of efficacious dose in complicated urinary tract infections
Part of Frontiers in Pharmacology, 2024
- DOI for Combining mathematical modeling, in vitro data and clinical target expression to support bispecific antibody binding affinity selection: a case example with FAP-4-1BBL
- Download full text (pdf) of Combining mathematical modeling, in vitro data and clinical target expression to support bispecific antibody binding affinity selection: a case example with FAP-4-1BBL
Pharmacogenetic testing or Therapeutic Drug Monitoring: A Quantitative Framework
Part of Clinical Pharmacokinetics, p. 871-884, 2024
- DOI for Pharmacogenetic testing or Therapeutic Drug Monitoring: A Quantitative Framework
- Download full text (pdf) of Pharmacogenetic testing or Therapeutic Drug Monitoring: A Quantitative Framework
Part of Cancer Chemotherapy and Pharmacology, p. 297-310, 2024
- DOI for Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children
- Download full text (pdf) of Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children
Part of Clinical Pharmacology and Therapeutics, p. 703-715, 2024
- DOI for Predicting the Long-Term Effects of Therapeutic Neutralization of Oncostatin M on Human Hematopoiesis
- Download full text (pdf) of Predicting the Long-Term Effects of Therapeutic Neutralization of Oncostatin M on Human Hematopoiesis
Part of Clinical Pharmacokinetics, p. 197-209, 2024
- DOI for Model-Informed Precision Dosing to Reduce Vincristine-Induced Peripheral Neuropathy in Pediatric Patients: A Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis
- Download full text (pdf) of Model-Informed Precision Dosing to Reduce Vincristine-Induced Peripheral Neuropathy in Pediatric Patients: A Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis
Part of International Journal of Antimicrobial Agents, 2024
- DOI for Impact of continuous-infusion meropenem degradation and infusion bag changes on bacterial killing of Pseudomonas aeruginosa based on model-informed translation
- Download full text (pdf) of Impact of continuous-infusion meropenem degradation and infusion bag changes on bacterial killing of Pseudomonas aeruginosa based on model-informed translation
Part of Clinical and Translational Science, 2024
- DOI for Integration of individual preclinical and clinical anti-infective PKPD data to predict clinical study outcomes
- Download full text (pdf) of Integration of individual preclinical and clinical anti-infective PKPD data to predict clinical study outcomes
Part of Scientific Reports, 2024
- DOI for Quantifying combined effects of colistin and ciprofloxacin against Escherichia coli in an in silico pharmacokinetic-pharmacodynamic model
- Download full text (pdf) of Quantifying combined effects of colistin and ciprofloxacin against Escherichia coli in an in silico pharmacokinetic-pharmacodynamic model
Part of CPT, p. 612-623, 2024
- DOI for Quantitative modeling of tumor dynamics and development of drug resistance in non-small cell lung cancer patients treated with erlotinib
- Download full text (pdf) of Quantitative modeling of tumor dynamics and development of drug resistance in non-small cell lung cancer patients treated with erlotinib
Multistate modeling for survival analysis in critically ill patients treated with meropenem
Part of CPT, p. 222-233, 2024
- DOI for Multistate modeling for survival analysis in critically ill patients treated with meropenem
- Download full text (pdf) of Multistate modeling for survival analysis in critically ill patients treated with meropenem
Part of International Immunopharmacology, 2024
- DOI for Bridging responses to a human telomerase reverse transcriptase-based peptide cancer vaccine candidate in a mechanism-based model
- Download full text (pdf) of Bridging responses to a human telomerase reverse transcriptase-based peptide cancer vaccine candidate in a mechanism-based model
Part of Cytokine, 2023
- DOI for Predicting cytokine kinetics during sepsis; a modelling framework from a porcine sepsis model with live Escherichia coli
- Download full text (pdf) of Predicting cytokine kinetics during sepsis; a modelling framework from a porcine sepsis model with live Escherichia coli
Part of CPT, p. 1804-1818, 2023
- DOI for A model‐based approach leveraging in vitro data to support dose selection from the outset: A framework for bispecific antibodies in immuno‐oncology
- Download full text (pdf) of A model‐based approach leveraging in vitro data to support dose selection from the outset: A framework for bispecific antibodies in immuno‐oncology
Part of CPT, p. 1305-1318, 2023
- DOI for Assessment of ibrutinib scheduling on leukocyte, lymph node size and blood pressure dynamics in chronic lymphocytic leukemia through pharmacokinetic-pharmacodynamic models
- Download full text (pdf) of Assessment of ibrutinib scheduling on leukocyte, lymph node size and blood pressure dynamics in chronic lymphocytic leukemia through pharmacokinetic-pharmacodynamic models
Part of Journal of Antimicrobial Chemotherapy, 2023
- DOI for Synergy of polymyxin B and minocycline against KPC-3- and OXA-48-producing Klebsiella pneumoniae in dynamic time-kill experiments: high agreement with in silico predictions
- Download full text (pdf) of Synergy of polymyxin B and minocycline against KPC-3- and OXA-48-producing Klebsiella pneumoniae in dynamic time-kill experiments: high agreement with in silico predictions
Part of Clinical and Translational Science, p. 73-84, 2023
- DOI for Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine-kinase inhibitors
- Download full text (pdf) of Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine-kinase inhibitors
Part of CPT, p. 1972-1987, 2023
- DOI for Model‐based assessment of neutrophil‐mediated phagocytosis and digestion of bacteria across in vitro and in vivo studies
- Download full text (pdf) of Model‐based assessment of neutrophil‐mediated phagocytosis and digestion of bacteria across in vitro and in vivo studies
Part of CPT, p. 1738-1750, 2023
- DOI for A multistate modeling and simulation framework to learn dose-response of oncology drugs: Application to bintrafusp alfa in non‐small cell lung cancer
- Download full text (pdf) of A multistate modeling and simulation framework to learn dose-response of oncology drugs: Application to bintrafusp alfa in non‐small cell lung cancer
Part of Journal of Antimicrobial Chemotherapy, 2023
Part of Microbiology Spectrum, 2023
- DOI for Prevalence and Clinical Consequences of Colistin Heteroresistance and Evolution into Full Resistance in Carbapenem-Resistant Acinetobacter baumannii
- Download full text (pdf) of Prevalence and Clinical Consequences of Colistin Heteroresistance and Evolution into Full Resistance in Carbapenem-Resistant Acinetobacter baumannii
Part of CPT, p. 154-167, 2023
- DOI for Rituximab pharmacokinetic and pharmacokinetic-pharmacodynamic evaluation based on a study in diffuse large B-cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity
- Download full text (pdf) of Rituximab pharmacokinetic and pharmacokinetic-pharmacodynamic evaluation based on a study in diffuse large B-cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity
Part of Clinical Pharmacology and Therapeutics, p. 851-858, 2023
- DOI for Multistate Pharmacometric Model to Define the Impact of Second-Line Immunotherapies on the Survival Outcome of the IMpower131 Study
- Download full text (pdf) of Multistate Pharmacometric Model to Define the Impact of Second-Line Immunotherapies on the Survival Outcome of the IMpower131 Study
Part of AAPS Journal, 2022
Part of Antibiotics, 2022
- DOI for Model-Informed Translation of In Vitro Effects of Short-, Prolonged- and Continuous-Infusion Meropenem against Pseudomonas aeruginosa to Clinical Settings
- Download full text (pdf) of Model-Informed Translation of In Vitro Effects of Short-, Prolonged- and Continuous-Infusion Meropenem against Pseudomonas aeruginosa to Clinical Settings
Part of Clinical Cancer Research, p. 1363-1371, 2022
- DOI for Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab
- Download full text (pdf) of Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab
Part of Journal of Antimicrobial Chemotherapy, p. 934-943, 2022
Part of Journal of Antimicrobial Chemotherapy, p. 2718-2728, 2022
- DOI for Population pharmacokinetics of apramycin from first-in-human plasma and urine data to support prediction of efficacious dose
- Download full text (pdf) of Population pharmacokinetics of apramycin from first-in-human plasma and urine data to support prediction of efficacious dose
Part of Frontiers in Microbiology, 2022
- DOI for Expert workshop summary: Advancing toward a standardized murine model to evaluate treatments for antimicrobial resistance lung infections
- Download full text (pdf) of Expert workshop summary: Advancing toward a standardized murine model to evaluate treatments for antimicrobial resistance lung infections
Part of Clinical Microbiology and Infection, p. 73-78, 2022
Part of Scientific Reports, 2022
- DOI for Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance
- Download full text (pdf) of Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance
Part of International Journal of Antimicrobial Agents, 2022
Pharmacokinetic/pharmacodynamic models for time courses of antibiotic effects
Part of International Journal of Antimicrobial Agents, 2022
- DOI for Pharmacokinetic/pharmacodynamic models for time courses of antibiotic effects
- Download full text (pdf) of Pharmacokinetic/pharmacodynamic models for time courses of antibiotic effects
Bayesian forecasting of tumor size metrics and overall survival
Part of CPT, p. 1604-1613, 2022
- DOI for Bayesian forecasting of tumor size metrics and overall survival
- Download full text (pdf) of Bayesian forecasting of tumor size metrics and overall survival
Research priorities towards precision antibiotic therapy to improve patient care
Part of LANCET MICROBE, 2022
- DOI for Research priorities towards precision antibiotic therapy to improve patient care
- Download full text (pdf) of Research priorities towards precision antibiotic therapy to improve patient care
Part of Clinical Microbiology and Infection, p. 1367-1374, 2022
- DOI for Translational in vitro and in vivo PKPD modelling for apramycin against Gram-negative lung pathogens to facilitate prediction of human efficacious dose in pneumonia
- Download full text (pdf) of Translational in vitro and in vivo PKPD modelling for apramycin against Gram-negative lung pathogens to facilitate prediction of human efficacious dose in pneumonia
Part of Pharmaceutical research, p. 1633-1643, 2022
Part of CPT, p. 527-528, 2021
- DOI for Dr. Hartmut Derendorf, PhD, a world-renowned expert in pharmacokinetics and pharmacometrics (1953–2020)
- Download full text (pdf) of Dr. Hartmut Derendorf, PhD, a world-renowned expert in pharmacokinetics and pharmacometrics (1953–2020)
Part of BMC Infectious Diseases, 2021
- DOI for Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity
- Download full text (pdf) of Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity
Part of Frontiers in Pharmacology, 2021
- DOI for Tissue Type Differences in ABCB1 Expression and Paclitaxel Tissue Pharmacokinetics in Patients With Esophageal Cancer
- Download full text (pdf) of Tissue Type Differences in ABCB1 Expression and Paclitaxel Tissue Pharmacokinetics in Patients With Esophageal Cancer
Part of EBioMedicine, 2021
- DOI for Antibacterial activity of apramycin at acidic pH warrants wide therapeutic window in the treatment of complicated urinary tract infections and acute pyelonephritis
- Download full text (pdf) of Antibacterial activity of apramycin at acidic pH warrants wide therapeutic window in the treatment of complicated urinary tract infections and acute pyelonephritis
Part of Clinical Pharmacology and Therapeutics, p. 1063-1073, 2021
- DOI for Model-Informed Drug Development for Antimicrobials: Translational PK and PK/PD Modeling to Predict an Efficacious Human Dose for Apramycin
- Download full text (pdf) of Model-Informed Drug Development for Antimicrobials: Translational PK and PK/PD Modeling to Predict an Efficacious Human Dose for Apramycin
Pivotal Role of Translation in Anti-Infective Development
Part of Clinical Pharmacology and Therapeutics, p. 856-866, 2021
- DOI for Pivotal Role of Translation in Anti-Infective Development
- Download full text (pdf) of Pivotal Role of Translation in Anti-Infective Development
Efficacy of EBL-1003 (apramycin) against Acinetobacter baumannii lung infections in mice
Part of Clinical Microbiology and Infection, p. 1315-1321, 2021
- DOI for Efficacy of EBL-1003 (apramycin) against Acinetobacter baumannii lung infections in mice
- Download full text (pdf) of Efficacy of EBL-1003 (apramycin) against Acinetobacter baumannii lung infections in mice
Model-Informed Drug Development for Anti-Infectives: State of the Art and Future
Part of Clinical Pharmacology and Therapeutics, p. 867-891, 2021
- DOI for Model-Informed Drug Development for Anti-Infectives: State of the Art and Future
- Download full text (pdf) of Model-Informed Drug Development for Anti-Infectives: State of the Art and Future
Part of CPT, p. 511-521, 2021
- DOI for Tumor growth inhibition modeling of individual lesion dynamics and interorgan variability in HER2-negative breast cancer patients treated with docetaxel
- Download full text (pdf) of Tumor growth inhibition modeling of individual lesion dynamics and interorgan variability in HER2-negative breast cancer patients treated with docetaxel
CPT: Pharmacometrics & Systems Pharmacology - Inception, Maturation, and Future Vision
Part of CPT, p. 649-657, 2021
- DOI for CPT: Pharmacometrics & Systems Pharmacology - Inception, Maturation, and Future Vision
- Download full text (pdf) of CPT: Pharmacometrics & Systems Pharmacology - Inception, Maturation, and Future Vision
Effect of Scalp Cooling on the Pharmacokinetics of Paclitaxel
Part of Cancers, 2021
- DOI for Effect of Scalp Cooling on the Pharmacokinetics of Paclitaxel
- Download full text (pdf) of Effect of Scalp Cooling on the Pharmacokinetics of Paclitaxel
Part of CPT, p. 1255-1266, 2021
- DOI for Multistate model for pharmacometric analyses of overall survival in HER2-negative breast cancer patients treated with docetaxel
- Download full text (pdf) of Multistate model for pharmacometric analyses of overall survival in HER2-negative breast cancer patients treated with docetaxel
Part of Cancer Reports, 2021
- DOI for Continuous infusion of piperacillin‐tazobactam significantly improves target attainment in children with cancer and fever
- Download full text (pdf) of Continuous infusion of piperacillin‐tazobactam significantly improves target attainment in children with cancer and fever
Model-based Dose Individualization of Sunitinib in Gastrointestinal Stromal Tumors
Part of Clinical Cancer Research, p. 4590-4598, 2020
Model-Based Biomarker Selection for Dose Individualization of Tyrosine-Kinase Inhibitors
Part of Frontiers in Pharmacology, 2020
- DOI for Model-Based Biomarker Selection for Dose Individualization of Tyrosine-Kinase Inhibitors
- Download full text (pdf) of Model-Based Biomarker Selection for Dose Individualization of Tyrosine-Kinase Inhibitors
Part of International Journal of Antimicrobial Agents, 2020
- DOI for Combination of polymyxin B and minocycline against multidrug-resistant Klebsiella pneumoniae: interaction quantified by pharmacokinetic/pharmacodynamic modelling from in vitro data
- Download full text (pdf) of Combination of polymyxin B and minocycline against multidrug-resistant Klebsiella pneumoniae: interaction quantified by pharmacokinetic/pharmacodynamic modelling from in vitro data
Part of Antimicrobial Agents and Chemotherapy, 2020
- DOI for Efficacy of Antibiotic Combinations against Multidrug-Resistant Pseudomonas aeruginosa in Automated Time-Lapse Microscopy and Static Time-Kill Experiments
- Download full text (pdf) of Efficacy of Antibiotic Combinations against Multidrug-Resistant Pseudomonas aeruginosa in Automated Time-Lapse Microscopy and Static Time-Kill Experiments
Part of Clinical Microbiology and Infection, p. 1214-1221, 2020
- DOI for Evaluation of polymyxin B in combination with 13 other antibiotics against carbapenemase-producing Klebsiella pneumoniae in time-lapse microscopy and time-kill experiments
- Download full text (pdf) of Evaluation of polymyxin B in combination with 13 other antibiotics against carbapenemase-producing Klebsiella pneumoniae in time-lapse microscopy and time-kill experiments
Pharmacometrics and Systems Pharmacology 2030
Part of Clinical Pharmacology and Therapeutics, p. 76-78, 2020
Part of Clinical Infectious Diseases, p. 2599-2607, 2020
Part of Clinical Microbiology and Infection, p. 1644-1650, 2020
- DOI for Population pharmacokinetics of colistin and the relation to survival in critically ill patients infected with colistin susceptible and carbapenem-resistant bacteria
- Download full text (pdf) of Population pharmacokinetics of colistin and the relation to survival in critically ill patients infected with colistin susceptible and carbapenem-resistant bacteria
Part of CPT, p. 115-123, 2020
- DOI for The tumor time-course predicts overall survival in non-small cell lung cancer patients treated with atezolizumab: dependency on follow-up time
- Download full text (pdf) of The tumor time-course predicts overall survival in non-small cell lung cancer patients treated with atezolizumab: dependency on follow-up time
Acinetobacter Infections: Reply to Wilson et al
Part of Clinical Infectious Diseases, p. 1358-1359, 2020
Part of Clinical Cancer Research, p. 4892-4900, 2020
Part of International Journal of Antimicrobial Agents, 2020
How preclinical infection models help define antibiotic doses in the clinic
Part of International Journal of Antimicrobial Agents, p. 106008, 2020
- DOI for How preclinical infection models help define antibiotic doses in the clinic
- Download full text (pdf) of How preclinical infection models help define antibiotic doses in the clinic
Part of Clinical Microbiology and Infection, p. 1185-1191, 2020
Acute bacterial or viral infection-What's the difference?: A perspective from PKPD modellers
Part of Clinical Microbiology and Infection, p. 1133-1136, 2020
Part of Antimicrobial Agents and Chemotherapy, 2020
Part of Molecular Pharmaceutics, p. 1458-1469, 2020
Part of Antimicrobial Agents and Chemotherapy, 2020
- DOI for Extension of Pharmacokinetic/Pharmacodynamic Time-Kill Studies To Include Lipopolysaccharide/Endotoxin Release from Escherichia coli Exposed to Cefuroxime.
- Download full text (pdf) of Extension of Pharmacokinetic/Pharmacodynamic Time-Kill Studies To Include Lipopolysaccharide/Endotoxin Release from Escherichia coli Exposed to Cefuroxime.
Part of International Journal of Infectious Diseases, p. 133-140, 2020
- DOI for Population pharmacokinetics of piperacillin in plasma and subcutaneous tissue in patients on continuous renal replacement therapy
- Download full text (pdf) of Population pharmacokinetics of piperacillin in plasma and subcutaneous tissue in patients on continuous renal replacement therapy
Part of Pediatric Blood & Cancer, 2019
Part of PLOS ONE, 2019
- DOI for A non-linear mixed effect model for innate immune response: In vivo kinetics of endotoxin and its induction of the cytokines tumor necrosis factor alpha and interleukin-6
- Download full text (pdf) of A non-linear mixed effect model for innate immune response: In vivo kinetics of endotoxin and its induction of the cytokines tumor necrosis factor alpha and interleukin-6
Part of Journal of Antimicrobial Chemotherapy, p. 2984-2993, 2019
- DOI for Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen
- Download full text (pdf) of Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen
Part of Clinical Infectious Diseases, p. 769-776, 2019
Part of British Journal of Clinical Pharmacology, p. 1484-1494, 2019
- DOI for Effects of cladribine tablets on heart rate, atrio-ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis
- Download full text (pdf) of Effects of cladribine tablets on heart rate, atrio-ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis
Part of Clinical Pharmacology and Therapeutics, p. 486-495, 2019
Association between Paclitaxel Clearance and Tumor Response in Patients with Esophageal Cancer
Part of Cancers, 2019
- DOI for Association between Paclitaxel Clearance and Tumor Response in Patients with Esophageal Cancer
- Download full text (pdf) of Association between Paclitaxel Clearance and Tumor Response in Patients with Esophageal Cancer
Part of Journal of Pharmaceutical Sciences, p. 630-640, 2019
- DOI for Model-Based Drug Development in Pulmonary Delivery: Pharmacokinetic Analysis of Novel Drug Candidates for Treatment of Pseudomonas aeruginosa Lung Infection
- Download full text (pdf) of Model-Based Drug Development in Pulmonary Delivery: Pharmacokinetic Analysis of Novel Drug Candidates for Treatment of Pseudomonas aeruginosa Lung Infection
Part of The Lancet - Infectious diseases, p. 391-400, 2018
Part of AAPS Journal, 2018
- DOI for Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in Oncology
- Download full text (pdf) of Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in Oncology
Part of Antimicrobial Agents and Chemotherapy, 2018
Part of British Journal of Clinical Pharmacology, p. 490-500, 2018
Part of Basic & Clinical Pharmacology & Toxicology, p. 407-422, 2018
Part of Pharmaceutical research, 2018
- DOI for A pharmacometric analysis of patient-reported outcomes in breast cancer patients through item response theory
- Download full text (pdf) of A pharmacometric analysis of patient-reported outcomes in breast cancer patients through item response theory
Reply to Prim et al., "Is Colistin Susceptibility Testing Finally on the Right Track?"
Part of Antimicrobial Agents and Chemotherapy, 2018
Part of Antimicrobial Agents and Chemotherapy, 2018
Predicting mutant selection in competition experiments with ciprofloxacin-exposed Escherichia coli
Part of International Journal of Antimicrobial Agents, p. 399-406, 2018
Part of CPT, p. 449-457, 2017
- DOI for Pharmacometric Modeling of Liver Metastases' Diameter, Volume, and Density and Their Relation to Clinical Outcome in Imatinib-Treated Patients With Gastrointestinal Stromal Tumors
- Download full text (pdf) of Pharmacometric Modeling of Liver Metastases' Diameter, Volume, and Density and Their Relation to Clinical Outcome in Imatinib-Treated Patients With Gastrointestinal Stromal Tumors
Part of Journal of Antimicrobial Chemotherapy, p. 3108-3116, 2017
Part of CPT, p. 418-429, 2017
Part of CPT, p. 373-382, 2017
- DOI for A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients
- Download full text (pdf) of A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients
Part of CPT, p. 543-551, 2017
- DOI for Item Response Theory to Quantify Longitudinal Placebo and Paliperidone Effects on PANSS Scores in Schizophrenia
- Download full text (pdf) of Item Response Theory to Quantify Longitudinal Placebo and Paliperidone Effects on PANSS Scores in Schizophrenia
Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring
Part of Cancer Chemotherapy and Pharmacology, p. 343-353, 2017
- DOI for Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring
- Download full text (pdf) of Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring
Part of Journal of Pharmacokinetics and Pharmacodynamics, 2017
Colistin is Extensively Lost during Standard in Vitro Experimental Conditions
Part of Antimicrobial Agents and Chemotherapy, 2017
Part of Antimicrobial Agents and Chemotherapy, 2017
Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 69-79, 2017
- DOI for A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection.
- Download full text (pdf) of A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection.
Part of Infectious Diseases, p. 521-527, 2017
Part of BMJ Open, 2016
- DOI for Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol
- Download full text (pdf) of Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol
Part of Journal of Antimicrobial Chemotherapy, p. 1881-1884, 2016
Part of Journal of Antimicrobial Chemotherapy, p. 1279-1290, 2016
Part of CPT, p. 173-181, 2016
- DOI for PK-PD Modeling of Individual Lesion FDG-PET Response to Predict Overall Survival in Patients With Sunitinib-treated Gastrointestinal Stromal Tumor
- Download full text (pdf) of PK-PD Modeling of Individual Lesion FDG-PET Response to Predict Overall Survival in Patients With Sunitinib-treated Gastrointestinal Stromal Tumor
Part of British Journal of Clinical Pharmacology, p. 717-727, 2016
Part of International Journal of Antimicrobial Agents, p. 337-341, 2016
Part of Pharmaceutical research, p. 1115-1125, 2016
Performance of Nonlinear Mixed Effects Models in the Presence of Informative Dropout
Part of AAPS Journal, p. 245-255, 2015
Part of Journal of Pharmacokinetics and Pharmacodynamics, 2015
Part of Clinical Pharmacology and Therapeutics, p. 37-54, 2015
A pharmacokinetic binding model for bevacizumab and VEGF(165) in colorectal cancer patients
Part of Cancer Chemotherapy and Pharmacology, p. 791-803, 2015
- DOI for A pharmacokinetic binding model for bevacizumab and VEGF(165) in colorectal cancer patients
- Download full text (pdf) of A pharmacokinetic binding model for bevacizumab and VEGF(165) in colorectal cancer patients
Part of Journal of Antimicrobial Chemotherapy, p. 3051-3060, 2015
Inter occasion variability in individual optimal design
Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 735-750, 2015
- DOI for Inter occasion variability in individual optimal design
- Download full text (pdf) of Inter occasion variability in individual optimal design
Part of Antimicrobial Agents and Chemotherapy, p. 7240-7248, 2015
Part of AAPS Journal, p. 994-1008, 2014
Part of Journal of Antimicrobial Chemotherapy, p. 1350-1361, 2014
Part of Pharmaceutical research, p. 3390-3403, 2014
Part of CPT, p. 1-10, 2014
Part of CPT, p. 1-11, 2014
CPT: Pharmacometrics & Systems Pharmacology Publishes Its 100th Article
Part of CPT, p. 1-2, 2014
Part of AAPS Journal, p. 533-541, 2013
Part of Journal of Pharmacokinetics and Pharmacodynamics, 2013
Characterising variability in warfarin dose requirements in children using modelling and simulation
Part of British Journal of Clinical Pharmacology, p. 158-169, 2013
Part of CPT, 2013
Part of CPT, 2013
Part of CPT, 2013
Tutorials on the foundations of pharmacometrics and systems pharmacology
Part of CPT, 2013
Part of European Journal of Clinical Pharmacology, p. 1275-1283, 2013
- DOI for Warfarin dose prediction in children using pharmacometric bridging: comparison with published pharmacogenetic dosing algorithms
- Download full text (pdf) of Warfarin dose prediction in children using pharmacometric bridging: comparison with published pharmacogenetic dosing algorithms
Part of Antimicrobial Agents and Chemotherapy, p. 668-671, 2013
Part of Pediatric Research, p. 68-74, 2013
A Pharmacogenetic Predictive Model for Paclitaxel Clearance Based on the DMET Platform
Part of Clinical Cancer Research, p. 5210-5217, 2013
CYP3A4*22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity
Part of Clinical Cancer Research, p. 3316-3324, 2013
Part of Journal of Pharmacokinetics and Pharmacodynamics, 2013
Part of Journal of Pharmacokinetics and Pharmacodynamics, 2013
Evaluation of IPPSE, an alternative method for sequential population PKPD analysis
Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 177-193, 2012
Integrated Population Pharmacokinetic Analysis of Voriconazole in Children, Adolescents, and Adults
Part of Antimicrobial Agents and Chemotherapy, p. 3032-3042, 2012
Part of Cancer Chemotherapy and Pharmacology, p. 1155-1163, 2012
Part of Investigational new drugs, p. 833-845, 2012
Part of Antimicrobial Agents and Chemotherapy, p. 179-188, 2012
Part of Cancer Chemotherapy and Pharmacology, p. 881-890, 2012
Part of Clinical Cancer Research, p. 5780-5787, 2012
Influence of drug exposure and genetic variation on paclitaxel-induced neurotoxicity
Part of Annals of Oncology, p. 534-534, 2012
Part of Antimicrobial Agents and Chemotherapy, p. 4241-4249, 2012
Influence of Polymorphic OATP1B-Type Carriers on the Disposition of Docetaxel
Part of Clinical Cancer Research, p. 4433-4440, 2012
Influence of Smoking on the Pharmacokinetics and Toxicity Profiles of Taxane Therapy
Part of Clinical Cancer Research, p. 4425-4432, 2012
Increased Clearance of Docetaxel in Androgen Deprived Prostate Cancer Patients
Part of European Journal of Cancer, p. 128-128, 2012
Part of Cancer Chemotherapy and Pharmacology, p. 591-601, 2012
Part of The Pharmacogenomics Journal, p. 113-120, 2011
Part of Antimicrobial Agents and Chemotherapy, p. 4619-4630, 2011
Part of Investigational new drugs, p. 984-995, 2011
Part of Antimicrobial Agents and Chemotherapy, p. 1571-1579, 2011
Part of Drug Metabolism And Disposition, p. 247-255, 2011
A CYP3A4 Phenotype-Based Dosing Algorithm for Individualized Treatment of Irinotecan
Part of Clinical Cancer Research, p. 736-742, 2010
Scaling the time-course of myelosuppression from rats to patients with a semi-physiological model
Part of Investigational new drugs, p. 744-753, 2010
Part of Journal of clinical pharmacology, p. 679-687, 2010
Part of Cancer Chemotherapy and Pharmacology, p. 839-848, 2010
- DOI for Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression
- Download full text (pdf) of Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression
Part of British Journal of Clinical Pharmacology, p. 815-824, 2010
Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 493-506, 2010
Part of European Journal of Cancer, p. 21-32, 2010
Part of Clinical Pharmacology and Therapeutics, p. 84-91, 2009
Part of Journal of Pharmaceutical and Biomedical Analysis, p. 760-767, 2009
Part of Pediatric Research, p. 574-579, 2009
Part of Clinical Pharmacology and Therapeutics, p. 387-395, 2009
Part of Clinical Pharmacology and Therapeutics, p. 409-417, 2009
The effect of decontamination procedures on the pharmacokinetics of venlafaxine in overdose
Part of Clinical Pharmacology and Therapeutics, p. 403-410, 2009
Part of American Journal of Clinical Nutrition, p. 290-296, 2009
Part of Clinical Pharmacology and Therapeutics, p. 387-395, 2009
A tool for neutrophil guided dose adaptation in chemotherapy
Part of Computer Methods and Programs in Biomedicine, p. 283-291, 2009
- DOI for A tool for neutrophil guided dose adaptation in chemotherapy
- Download full text (pdf) of A tool for neutrophil guided dose adaptation in chemotherapy
Part of Therapeutic Drug Monitoring, p. 457-466, 2009
Part of Antimicrobial Agents and Chemotherapy, p. 3430-3436, 2009
Part of Clinical Pharmacokinetics, p. 253-263, 2009
Part of Intensive Care Medicine, p. 197-197, 2007
Cigarette smoking and irinotecan treatment: Pharmacokinetic interaction and effects on neutropenia
Part of Journal of Clinical Oncology, p. 2719-2726, 2007
Pharmacokinetics of quetiapine in overdose and the effect of activated charcoal
Part of Clinical Pharmacology and Therapeutics, p. 821-827, 2007
Part of Intensive Care Medicine, p. 739-739, 2007
Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein
Part of Clinical Pharmacology and Therapeutics, p. 42-49, 2007
Activated charcoal decreases the risk of QT prolongation after citalopram overdose
Part of Annals of Emergency Medicine, p. 593-600, 2007
Human methyl parathion poisoning
Part of Clinical Toxicology, p. 956-960, 2007
Part of Clinical Pharmacokinetics, p. 1099-1114, 2006
Part of European Journal of Pharmaceutical Sciences, p. 163-173, 2005
Pharmacokinetic/pharmacodynamic modelling in oncological drug development.
Part of Basic Clin Pharmacol Toxicol, p. 206-11, 2005
Part of Eur J Pharm Sci, p. 163-73, 2005
Pharmacodynamic differences between species exemplified by the novel anticancer agent CHS 828
Part of Drug development research, p. 218-226, 2004
Mechanistic models for myelosuppression
Part of Investigational new drugs, p. 183-194, 2003
Model of Chemotherapy-Induced Myelosuppression With Parameter Consistency Across Drugs
Part of Journal of Clinical Oncology, p. 4713-4721, 2002
Model of chemotherapy-induced myelosuppression with parameter consistency across drugs
Part of Journal of Clinical Oncology, p. 4713-4721, 2002
Part of Cancer Chemotherapy and Pharmacology, p. 493-500, 2000
Articles, review/survey
Model-informed precision dosing: State of the art and future perspectives
Part of Advanced Drug Delivery Reviews, 2024
- DOI for Model-informed precision dosing: State of the art and future perspectives
- Download full text (pdf) of Model-informed precision dosing: State of the art and future perspectives
Variability of murine bacterial pneumonia models used to evaluate antimicrobial agents
Part of Frontiers in Microbiology, 2022
- DOI for Variability of murine bacterial pneumonia models used to evaluate antimicrobial agents
- Download full text (pdf) of Variability of murine bacterial pneumonia models used to evaluate antimicrobial agents
From Therapeutic Drug Monitoring to Model-Informed Precision Dosing for Antibiotic
Part of Clinical Pharmacology and Therapeutics, p. 928-941, 2021
Considerations for the optimal management of antibiotic therapy in elderly patients
Part of Journal of Global Antimicrobial Resistance, p. 325-333, 2020
- DOI for Considerations for the optimal management of antibiotic therapy in elderly patients
- Download full text (pdf) of Considerations for the optimal management of antibiotic therapy in elderly patients
Semi-mechanistic pharmacokinetic-pharmacodynamic modelling of antibiotic drug combinations
Part of Clinical Microbiology and Infection, p. 697-706, 2018
Part of Intensive Care Medicine, p. 1021-1032, 2017
Part of British Journal of Clinical Pharmacology, p. 56-71, 2015
- DOI for Population pharmacokinetic pharmacodynamic modelling in oncology: a tool for predicting clinical response
- Download full text (pdf) of Population pharmacokinetic pharmacodynamic modelling in oncology: a tool for predicting clinical response
Pharmacokinetic-Pharmacodynamic Modeling of Antibacterial Drugs
Part of Pharmacological Reviews, p. 1053-1090, 2013
Systematic Review and Meta-Analysis of In Vitro Synergy of Polymyxins and Carbapenems
Part of Antimicrobial Agents and Chemotherapy, p. 5104-5111, 2013
Part of Basic & Clinical Pharmacology & Toxicology, p. 234-242, 2010